Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
0.6920
-0.0300 (-4.16%)
At close: Aug 28, 2025, 4:00 PM
0.6999
+0.0079 (1.14%)
After-hours: Aug 28, 2025, 5:38 PM EDT
Iterum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
30.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ITRM News
- 8 days ago - Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - GlobeNewsWire
- 23 days ago - Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Iterum Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewsWire
- 2 months ago - Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - GlobeNewsWire
- 2 months ago - Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence - GlobeNewsWire
- 2 months ago - Iterum Therapeutics Announces Partnership for Commercialization Services - GlobeNewsWire